Xaluritamig, A STEAP1-Targeted Immune Therapy for The Treatment of Prostate Cancer
Time: 8:30 am
day: Day 1
Details:
- Designing a T-cell engager that selectively targets STEAP1-high tumors
- Specificity and efficacy of AMG 509 in preclinical models
- A brief update on the clinical trials status of AMG 509
